2023-505796-76-00CompletedPhase 1
Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN
Source: EU CTIS (euclinicaltrials.eu) · Last updated 6 Jun 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 10 Aug 2023
- Start date
- 18 Jan 2024
- Lead sponsor
- Merck Healthcare KGaA
- Diseases
- Head and neck cancer
- EU CT number
- 2023-505796-76-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 12
- 10 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (10)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Antwerp University Hospital | Edegem | Belgium | Completed |
| Universitair Ziekenhuis Gent | Gent | Belgium | Completed |
| Algemeen Ziekenhuis Groeninge | Kortrijk | Belgium | Completed |
| Hopital De Libramont | Libramont-Chevigny | Belgium | Completed |
| Vitaz | Sint-Niklaas | Belgium | Completed |
| Institut Català d'Oncologia | Girona | Spain | Completed |
| Hospital Universitario Lucus Augusti | Lugo | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz | Madrid | Spain | Completed |
| Clinica Universidad de Navarra | Madrid | Spain | Completed |
| University Hospital Virgen Del Rocio S.L. | Sevilla | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.